Supreme Court is Asked to Review State Secrets Case
Attorneys for Khaled El-Masri, who was allegedly subjected to “extraordinary rendition” by the Central Intelligence Agency, asked the U.S. Supreme Court to review the dismissal of his lawsuit against the Agency last year on asserted “state secrets” grounds.
If the petition (pdf) is granted, the Court’s review has the potential to alter the judiciary’s handling of “state secrets” claims generally.
“The proliferation of cases in which the government has invoked the state secrets privilege, and the lack of guidance from this Court since its 1953 decision in Reynolds, have produced conflict and confusion among the lower courts regarding the proper scope and application of the privilege,” the petitioners argued. See Petition for Certiorari, May 30, 2007.
The government replied last week that the petition is an “extravagant request” to overturn “settled precedents” and should be rejected. See Government’s Opposition to Petition for Certiorari (pdf), September 2007.
The historical and legal background of the controversy over use of the state secrets privilege was examined most recently by legal scholar Louis Fisher in “The State Secrets Privilege: Relying on Reynolds,” Political Science Quarterly, Fall 2007 (subscription required).
A critical view of state secrets policy was presented by journalist Barry Siegel in “State-Secret Overreach,” Los Angeles Times, September 16.
The transition to a clean energy future and diversified sources of energy requires a fundamental shift in how we produce and consume energy across all sectors of the U.S. economy.
A deeper understanding of methane could help scientists better address these impacts – including potentially through methane removal.
While it is reasonable for governments to keep the most sensitive aspects of nuclear policies secret, the rights of their citizens to have access to general knowledge about these issues is equally valid so they may know about the consequences to themselves and their country.
Advancing the U.S. leadership in emerging biotechnology is a strategic imperative, one that will shape regional development within the U.S., economic competitiveness abroad, and our national security for decades to come.